Confronto

Glepaglutide vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

396091-73-9

Peso molecolare

nessun dato

1047.21 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Pasireotid
Germania	Non approvato	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?: Glepaglutide is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?: Germania: Glepaglutide — Non approvato, Pasireotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Pasireotid

Germania

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?

Glepaglutide is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?

Germania: Glepaglutide — Non approvato, Pasireotid — Su prescrizione. Stati Uniti: Glepaglutide — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.